Abbott Laboratories Q1 Earnings Call Highlights

2 months ago 21

MarketBeat

Thu, April 16, 2026 astatine 10:07 AM CDT 8 min read

Abbott Laboratories logo

Exact Sciences acquisition: Abbott closed the woody March 23 and expects it to adhd astir $3 billion of incremental income successful 2026, portion causing $0.20 of near-term EPS dilution that lowers the full-year adjusted EPS midpoint to $5.48; the institution has moved to comparable income reporting and acceptable a 2026 income maturation outlook of 6.5%–7.5% connected a comparable basis.
Q1 successful enactment but mixed drivers: Adjusted EPS was $1.15 and comparable income roseate 3.7%, but a overmuch weaker respiratory play drove a ~10% diminution successful rapid/molecular diagnostics adjacent arsenic crab diagnostics (+13%), devices (notably electrophysiology), and established pharmaceuticals showed beardown growth.
Outlook and catalysts: Abbott guided Q2 adjusted EPS of $1.25–$1.31, expects FX to beryllium astir neutral, and anticipates acceleration successful the 2nd fractional of 2026 driven by nutrition execution, expanding PFA/electrophysiology launches, Core Lab betterment and integration of Exact Sciences.
Interested successful Abbott Laboratories? Here are 5 stocks we similar better.

A Dividend King connected Sale: Is Abbott Labs a Healthcare Bargain?

Abbott Laboratories (NYSE:ABT) reported first-quarter 2026 results that absorption said were “aligned with our expectations for the commencement of the year,” arsenic the institution absorbed weaker respiratory investigating request and earlier-than-planned financing costs tied to its recently closed acquisition of Exact Sciences.

Chairman and CEO Robert Ford said Abbott delivered adjusted net per stock of $1.15, accordant with guidance, contempt “a weaker than expected respiratory season.” The 4th besides marked “an important strategical milestone,” helium said, with the completion of the Exact Sciences woody connected March 23.

→ 5 Space Stocks Already Climbing Ahead of the SpaceX IPO

AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal

Ford said the Exact Sciences acquisition “adds a caller high-growth concern to the Abbott portfolio,” strengthening Abbott’s diagnostics enactment and expanding into crab diagnostics. He reiterated Abbott’s anticipation that Exact Sciences volition adhd astir $3 cardinal of incremental income successful 2026 and accelerate Abbott’s semipermanent income maturation rate.

CFO Phil Boudreau said first-quarter reported results see Exact Sciences from the adjacent day done quarter-end, but Abbott is present emphasizing comparable income growth metrics that see Exact Sciences income successful some the anterior and current-year periods. “To align with our reporting of comparable income growth, our afloat twelvemonth 2026 income maturation outlook of 6.5%–7.5% is present connected a comparable ground arsenic well,” Boudreau said.

Read Entire Article